| Literature DB >> 27582728 |
Brandon Cieniewicz1, Alexis L Santana1, Nana Minkah1, Laurie T Krug1.
Abstract
Herpesviruses establish a chronic infection in the host characterized by intervals of lytic replication, quiescent latency, and reactivation from latency. Murine gammaherpesvirus 68 (MHV68) naturally infects small rodents and has genetic and biologic parallels with the human gammaherpesviruses (gHVs), Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus. The murine gammaherpesvirus model pathogen system provides a platform to apply cutting-edge approaches to dissect the interplay of gammaherpesvirus and host determinants that enable colonization of the host, and that shape the latent or lytic fate of an infected cell. This knowledge is critical for the development of novel therapeutic interventions against the oncogenic gHVs. The nuclear factor kappa B (NF-κB) signaling pathway is well-known for its role in the promotion of inflammation and many aspects of B cell biology. Here, we review key aspects of the virus lifecycle in the host, with an emphasis on the route that the virus takes to gain access to the B cell latency reservoir. We highlight how the murine gammaherpesvirus requires components of the NF-κB signaling pathway to promote replication, latency establishment, and maintenance of latency. These studies emphasize the complexity of gammaherpesvirus interactions with NF-κB signaling components that direct innate and adaptive immune responses of the host. Importantly, multiple facets of NF-κB signaling have been identified that might be targeted to reduce the burden of gammaherpesvirus-associated diseases.Entities:
Keywords: NF-kappaB; gammaherpesvirus; latency; pathogenesis
Year: 2016 PMID: 27582728 PMCID: PMC4987367 DOI: 10.3389/fmicb.2016.01202
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Comparison of select gammaherpesviruses.
| Murine gammaherpesvirus 68 (MHV68) | Herpesvirus saimiri (HVS) | Kaposi’s sarcoma-associated herpesvirus (KSHV) | Epstein–Barr virus (EBV) | |
|---|---|---|---|---|
| Formal name | Murid herpesvirus 4 | Saimiriine herpesvirus 2 | Human herpesvirus 8 | Human herpesvirus 4 |
| Classification | Rhadinovirus | Rhadinovirus | Rhadinovirus | Lymphocryptovirus |
| Natural host | Wood mice | Squirrel monkey | Humans | Humans |
| Transmission | Likely sexual | Likely by contact, fomites, aerosol | Saliva, sexual | Saliva, sexual |
| Associated diseases | Increased incidence lymphoproliferative disease, lymphoproliferative disease and fibrosis in immune deficient mice | Hematologic malignancies in non-native new world primates | Primary effusion lymphomas, Kaposi’s sarcoma, Multicentric Castleman’s disease, AIDS-associated lymphoproliferative disease | Infectious mononucleosis, Burkitt’s lymphoma, gastric carcinoma, nasopharyngeal carcinoma, Hodgkin’s disease, post-transplant and AIDS-associated lymphoproliferative disease |
| Cell targets | Endothelial cells, epithelial cells, fibroblasts, B lymphocytes, dendritic cells macrophages | Epithelial cells, T lymphocytes | Endothelial cells, B lymphocytes, monocytes, epithelial cells | Epithelial cells, B lymphocytes |
| Major latency reservoir | B lymphocytes, Macrophage cells | T lymphocytes | B lymphocytes | B lymphocytes |
| Latency maintenance | Episome tethering to host chromosome via LANA, chromatin silencing | Episome tethering to host chromosome via LANA, chromatin silencing | Episome tethering to host chromosome via LANA, chromatin silencing | Episome tethering to host chromosome via EBNA1, chromatin silencing |
| Triggers of reactivation | Terminal differentiation to plasma cells, inhibition of histone deacetylases, TLR stimulation, induced expression of viral transactivator RTA | Inhibition of histone deacetylases, induced expression of viral transactivator RTA | Inhibition of histone deacetylases, induced expression of viral transactivator RTA | Terminal differentiation to plasma cells, inhibition of histone deacetylases, induced expression of viral transactivators Zebra and RTA |
In vivo studies of the role of NF-κB signaling on MHV68 pathogenesis.
| Gene | Knockout | Immune defects | Route/Dose | Impact on pathogenesis | Changes in host response | Reference |
|---|---|---|---|---|---|---|
| LTα | Germline | No lymph nodes | INa/2 × 105,b | ↓ Clearance from lung | ↑ Lung inflammation | |
| ↑ Latency | ↓ CD8+ T cell activation | |||||
| CD40 | Germline | No germinal center formation | IN/1 × 103 | ↑ Reactivation | ||
| ↑ Infection of naïve B cell | ||||||
| Recrudescence in lungs | ||||||
| CD40 | Mixed BM chimera | IN/4 × 102 | Equal latency establishment Loss of latency in CD40-/- subset | Exclusion of CD40-/- B cells from germinal center | ||
| BAFFR | Germline | ↓ Mature B cells Impaired Abc production | IN/1 × 104 | ↓ Latency at 30 dpid | ↓ Germinal centers | |
| ↓ MHV68-specific Ab | ||||||
| IPe/1 × 105 | ↑ Viral titer at 3 dpi, | |||||
| ↓ Infection from 8–30 dpi | ||||||
| TLR2/9 | Germline | IN/5 × 104 | ↑ Viral load at 3 dpi | |||
| TLR3 | Germline | IN/1 × 103 | None | |||
| TLR7 | Germline | IP/1 × 105 | None | |||
| TLR9 | Germline | IP/1 × 105 | ↑ Reactivation | |||
| MyD88 | Germline | ↓ B cell activation | IN/1 × 103 | ↓ Latency in spleen at 16 dpi | ↓ B cell activation | |
| No difference in latency at 90 dpi | ↓ Germinal centers | |||||
| ↓ Class switching | ||||||
| Delayed ab production | ||||||
| IP/1 × 103 | ↑ Reactivation in PECs | |||||
| ↓ Reactivation in spleen | ||||||
| Mixed BM f Chimera | IN/1 × 103 | ↓ Latency | ↓ MyD88-/- germinal center entry | |||
| IkBaM | Viral Transgene | IN/1 × 103 | ↓ Latency establishment | |||
| ↓ Infected lung B cells | ||||||
| IP/1 × 103 | ↓ Viral titer | |||||
| ↓ Latency | ||||||
| p50 | Germline | ↓ B cell proliferation | IN/1 × 102 | ↑ Viral titers in lung | ↓ Antibody production | |
| ↓ Ab levels | ↓ Latency at 16 dpi | ↓ Vβ4+ T cell | ||||
| ↓ Germinal centers | ↑ Latency over time | |||||
| Recrudescence in lungs | ||||||
| Mixed BM chimera | None | IN/1 × 102 | Normal lung titers | ↓ p50-/- germinal center B cell | ||
| ↓ Latency in p50-/- B cells | ||||||
| Recrudescence in lungs | ||||||